EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics
CL Arteaga, JA Engelman - Cancer cell, 2014 - cell.com
ERBB receptors were linked to human cancer pathogenesis approximately three decades
ago. Biomedical investigators have since developed substantial understanding of the …
ago. Biomedical investigators have since developed substantial understanding of the …
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
LV Sequist, JCH Yang, N Yamamoto… - Journal of clinical …, 2013 - ascopubs.org
Purpose The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with
afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling …
afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling …
Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling
E Hirata, MR Girotti, A Viros, S Hooper… - Cancer cell, 2015 - cell.com
Intravital imaging of BRAF-mutant melanoma cells containing an ERK/MAPK biosensor
reveals how the tumor microenvironment affects response to BRAF inhibition by PLX4720 …
reveals how the tumor microenvironment affects response to BRAF inhibition by PLX4720 …
[HTML][HTML] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer …
ACZ Gelatti, A Drilon, FC Santini - Lung cancer, 2019 - Elsevier
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …
R Rosell, E Carcereny, R Gervais… - The lancet …, 2012 - thelancet.com
Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
R Katayama, AT Shaw, TM Khan… - Science translational …, 2012 - science.org
Most anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancers (NSCLCs)
are highly responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). However …
are highly responsive to treatment with ALK tyrosine kinase inhibitors (TKIs). However …
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
N Karachaliou, M Gonzalez-Cao… - … in medical oncology, 2018 - journals.sagepub.com
Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or
can be upregulated via interferon gamma (IFN-γ). We have explored whether the expression …
can be upregulated via interferon gamma (IFN-γ). We have explored whether the expression …
[HTML][HTML] Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non …
kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non …